Savara Inc. SVRA
4.75 USD +0.02 (+0.42%)
At closeNov 3, 2026, 6:17 PM EST
4.78 +0.03 +0.63%
After hours · Nov 3, 6:17 PM ET
4.66 Day range 4.88
3.86 52-week range 7.01
- YTD
- -21.23%
- 1 year
- +11.24%
- Market cap
- 973.40M
- EPS (ttm)
- -0.58
- Shares out
- 205.46M
- Forward P/E
- -13.49
- YTD return
- -21.23%
- 1-year return
- +11.24%
- Volume
- 2.11M
- Avg volume
- 1.99M
- Open
- 4.78
- Previous close
- 4.73
- Day's range
- 4.66 – 4.88
- 52-week range
- 3.86 – 7.01
- Beta
- 0.20
- Analysts
- Strong Buy
- Price target
- 11.06 (+132.7%)
- Earnings date
- Nov 11, 2026
2Y +1.04 (+28.11%)
Key statistics
- Enterprise value
- 1.13B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 8.76
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -57.19M
- Total cash
- 174.82M
- Total debt
- 30.41M
- Return on equity
- -105.48%
- Short % of float
- 16.35%
- 50-day average
- 5.10
- 200-day average
- 5.40
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 11.06 +132.7% upside
Now 4.75
- Target (low)
- 9.00
- Target (mean)
- 11.06
- Target (high)
- 16.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy3
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate -0.16898.
Financials — quick view
SVRA Revenue — quarterly 0
SVRA Net income — quarterly -40.23M
SVRA EPS — quarterly -0.16
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.16333 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.14125 | -0.16 | -0.02 | -13.27% |
| May 12, 2026 | Mar 31, 2026 | -0.14 | -0.15 | -0.01 | -7.14% |
| Mar 13, 2026 | Dec 31, 2025 | -0.12 | -0.13 | -0.01 | -8.33% |
| Nov 12, 2025 | Sep 30, 2025 | -0.13 | -0.14 | -0.01 | -7.69% |
| Aug 13, 2025 | Jun 30, 2025 | -0.12 | -0.14 | -0.02 | -16.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | JP Morgan | init | — | Overweight |
| Dec 23, 2025 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 18, 2025 | Wells Fargo | main | Overweight | Overweight |
| Nov 14, 2025 | Oppenheimer | main | Outperform | Outperform |
| Nov 13, 2025 | Citizens | main | Market Outperform | Market Outperform |
| Oct 23, 2025 | JMP Securities | main | Market Outperform | Market Outperform |
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- savarapharma.com
News
Savara Inc. (NASDAQ:SVRA) Sees Significant Drop in Short Interest 
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment 
Savara Presents Clinical Trial Post-Hoc Analysis Of IMPALA At CHEST 2026 Annual Meeting To Evaluate Effects Of Molgramostim In aPAP Patients 
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment 
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026 
JP Morgan Initiates Coverage On Savara with Overweight Rating, Announces Price Target of $12 
BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday 
BlackRock Inc. Takes $76.97 Million Position in Savara Inc. $SVRA 
Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRA 
Deutsche Bank AG Makes New $5.33 Million Investment in Savara Inc. $SVRA
Your note
Sign in to keep a note on SVRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ELAM NEVAN C | Director | Stock Award(Grant) | Dec 8, 2025 | 106,887 |
| ERICKSON ANNE | Officer | Stock Award(Grant) | Dec 11, 2024 | 434,672 |
| HAWKINS RICHARD JAMES | Director | Stock Award(Grant) | Dec 8, 2025 | 161,326 |
| LOWRANCE DAVID L. CPA | Chief Financial Officer | Sale | Jun 21, 2026 | 536,032 |
| LUTZ ROBERT MATTHEW | Chief Operating Officer | Stock Award(Grant) | Jul 14, 2026 | 328,977 |
| MCCRACKEN JOSEPH S | Director | Conversion of Exercise of derivative security | Feb 12, 2026 | 302,644 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEA Management Company, LLC | 11.91% | 24,471,264 | 121.13M | Jun 29, 2026 |
| Bain Capital Life Sciences Investors, LLC | 8.57% | 17,600,621 | 87.12M | Jun 29, 2026 |
| Venrock Adviser, LLC | 7.18% | 14,745,943 | 72.99M | Jun 29, 2026 |
| Deerfield Management Company, L.P | 6.60% | 13,569,000 | 67.17M | Jun 29, 2026 |
| Blackrock Inc. | 6.08% | 12,494,498 | 61.85M | Jun 29, 2026 |
| TCG Crossover Management, LLC | 6.02% | 12,362,205 | 61.19M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.00% | 6,164,961 | 30.52M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.93% | 3,969,421 | 19.65M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.55% | 3,183,757 | 15.76M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.81% | 1,672,858 | 8.28M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.76% | 1,555,905 | 7.70M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.69% | 1,421,946 | 7.04M | Sep 29, 2026 |